Tuas Biomedical Park, Singapore welcomes China-based WuXi Biologics to its cluster of biotechnology companies. The new facility will be a CRDMO Center a first of its kind in Singapore.
WuXi Biologics joins the Tuas Biomedical Cluster
Wuxi Biologics is a research and development company that spearheads Contract Research Development and Manufacturing Organization (CRDMO). The biotechnology company, founded in 2015, is based in China and as of 2021 has 18 manufacturing sites worldwide.
WuXi Biologics first announced its investment in Singapore last 2022 and as of Q1 2024, the company finally broke ground on its CRDMO facility–a first of its kind in Singapore. The facility is estimated at $1.4 billion and will focus on offering research & development, and manufacturing solutions.
The new CRDMO facility in Singapore’s Tuas Biomedical Park will feature a bioreactor that will add 120,000L to the global manufacturing capacity of WuXi Biologics. This new development is estimated to employ 1,500 additional staff.
According to the Economic Development Board Chairman, Mr. Png Cheong Boon, the CRDMO center of WuXi Biologics will strengthen Singapore’s biopharmaceutical center. WuXi Biologics’ investment will also provide significant employment opportunities and prompt collaborations among biomedical institutions.
Read also: Singapore-Malaysia RTS Link: Connecting Both Countries as Early as Q4 2026
Tuas Biomedical Park in Singapore: A hub purposely designed for seamless operations
The Tuas Biomedical Park (TBP) is a biomedical cluster by JTC Corporation and is located in western Singapore. The Biomedical Park sits at Tuas View and is near Jurong Port and Tuas Checkpoint, Malaysia.
The park is divided into two clusters, the Tuas Biomedical Park I which is a 183-hectare big complex, and the Tuas Biomedical Park II which is a 188-hectare big complex. In total, the Tuas Biomedical Park is a massive 280-hectare estate that is home to several global biotechnology companies.
The Tuas Biomedical Park is complete with all the necessary infrastructures for the companies that reside there. The estate has the essential utilities from roads, gas, power, and water lines. The park also features utilities from steam, natural gas, and water treatment systems. The TBP also features lush greenery and landscaping.
The park takes pride in its design with purpose-built spaces and low-voltage cables. With the purposeful design of the Tuas Biomedical Park, biomedical companies can quickly set up their operations in little time.
This marks the park as a world-class hub of choice for several well-known pharmaceutical, biotechnology, and medical companies. Some of the major global companies that operate in the TBP are Pfizer, GlaxoSmithKline, Wyeth, and Merck.
Singapore’s continuous pursuit of excellence
Singapore, recognized as one of the world leaders in biomedical science, continues its pursuit of excellence in the field. The country is driven by a commitment to research breakthroughs and cutting-edge technologies, hoisting Singapore as one of the leaders in drug research and development.
According to the Chief Scientific Officer at the Experimental Drug Development Centre (EDDC) Dr. Hao Weidong, Singapore’s advancement in the biomedical field was possible through the support of the government, business partnerships, and undying pursuit of excellence.
Read also:
Vietnam-Singapore Submarine Cable to Support Vietnam’s Growing Digital Sector, Operational by 2027
Singapore’s largest floating solar power plant project EIA completed
